Fusion Pharmaceuticals Inc. Common Shares
FUSN
FUSN was delisted on the 3rd of June, 2024.
41 hedge funds and large institutions have $235M invested in Fusion Pharmaceuticals Inc. Common Shares in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 5
37% more capital invested
Capital invested by funds: $172M → $235M (+$63.1M)
8% more funds holding
Funds holding: 38 → 41 (+3)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$20.7M |
| 2 |
EHI
Eagle Health Investments
Greenwich,
Connecticut
|
+$2.94M |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$271K |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$198K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$141K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$2.49M |
| 2 |
AG
Artal Group
Luxembourg
|
-$1.08M |
| 3 |
Millennium Management
New York
|
-$299K |
| 4 |
Two Sigma Investments
New York
|
-$59.1K |
| 5 |
VF
Virtu Financial
New York
|
-$49K |
FUSN Hedge Fund Activity: Q2 2023 in Review
41 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) for Q2 2023, worth a combined $235M — up 37% from $172M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new FUSN positions and 2 closed out — a net gain of 3 holders — while 10 added to existing stakes and 5 trimmed.
The largest buyer was Federated Hermes, adding an estimated $20.7M. The largest seller was RA Capital Management, exiting entirely with an estimated $2.49M sold.
- 41 institutional investors held Fusion Pharmaceuticals Inc. Common Shares (FUSN) as of Q2 2023, up from 38 in Q1 2023.
- Funds reported $235M of Fusion Pharmaceuticals Inc. Common Shares stock for Q2 2023, up 37% quarter-over-quarter.
- 5 funds opened new Fusion Pharmaceuticals Inc. Common Shares positions in Q2 2023 and 2 closed out, a net change of +3 holders.
- The largest Fusion Pharmaceuticals Inc. Common Shares buyer in Q2 2023 was Federated Hermes, an estimated $20.7M added.
- The largest Fusion Pharmaceuticals Inc. Common Shares seller in Q2 2023 was RA Capital Management, an estimated $2.49M sold.
Based on aggregated 13F filings for Q2 2023.